Biacore to launch Biacore® T100 – the most advanced system to-date for protein interaction analysis

System’s unmatched performance designed to meet the wide-ranging application needs of both academic and industrial customers.

Uppsala, Sweden, January 27, 2005. Biacore International AB (Biacore) (Stockholmsbörsen: BCOR) announced today that the launch of its new system Biacore® T100 will take place at the Association of Biomolecular Resource Facilities (ABRF) annual meeting in Savannah, Georgia on February 5-8. Biacore® T100 is expected to become the Company’s new flagship system based on its flexibility to meet a broad range of protein interaction analysis applications. The new system will be used across the life science research spectrum from basic research through drug discovery and development to manufacturing and QC. Biacore® T100 will complement the new array system that was introduced towards the end of 2004, considerably strengthening Biacore’s high-end product offering. Biacore® T100 will provide both academic and industrial life scientists with the highest quality real-time information possible about how a protein interacts with other proteins, or low-molecular weight compounds such as potential drug candidates. This unique information strongly supports confident, well-informed decision-making, for example, when elucidating disease pathways, defining therapeutic targets, selecting drug candidates with the greatest chance of success or contributing to decisions on the safety of protein therapeutics in terms of the immune responses generated. Important applications such as antibody characterization can be completed in days rather than weeks. Erik Walldén, Biacore’s President and CEO, said: “This is an extremely exciting launch for our company. Biacore® T100 will become our new flagship system as it incorporates all of the skills and expertise developed over the past 15 years. The system’s capabilities reflect the continuous customer feedback that we receive since we first introduced real-time protein interaction analysis into the life science market. The new Biacore® T100 will play a key role in strengthening our core business with academic customers as well as growing our sales with pharmaceutical and biotech companies. We anticipate that Biacore® T100 will quickly become Biacore’s largest-selling system.” The Company will present information on Biacore® T100 and its applications during the ABRF meeting and on its web site, www.biacore.com – Ends – About Biacore Biacore is a global supplier of systems for protein interaction analysis, an area of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. The Company's systems generate unique data on the interactions between proteins and other molecules, including small molecules such as drug candidates. During research, development and manufacture, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics. Biacore’s products are used in key areas such as antibody characterization, proteomics, lead characterization, immunogenicity, biotherapeutic development and production. The Company offers a range of products to meet specific application needs. Customers include leading life science research centers, all of the leading global pharmaceutical companies, and a large number of companies in the emerging biotechnology sector. Biacore also markets food analysis solutions, providing key manufacturers with a system and ready-to-use kits for the determination of food quality and safety. The company has its own direct sales capability in the world's key markets (United States, Europe, Japan, Australia) and a distribution network in Asia-Pacific. Biacore was founded in 1984 and is listed on the Stockholm Stock Exchange (SSE:BCOR). Further information on Biacore can be found at: www.biacore.com Cautionary Statement This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Biacore is a trademark of Biacore AB. For further information, please contact: Erik Walldén, President and CEO +41 (0) 79 769 4542 Scientific/Trade Press Enquiries: Sue Cresswell Market Communication Director +41 (0) 79 710 8311

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com

Documents & Links